Lombard Medical, Inc.(NASDAQ:EVAR)

June 2016

This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995,as amended. These forward-looking statements are based on management’s current expectations, but are subject to risks anduncertainties that could cause actual results to differ materially from either historical or anticipated results depending on a variety offactors. All statements contained in this presentation that do not describe historical facts may constitute forward-lookingstatements. Statements that address activities, events or developments that we expect or anticipate may occur in the future,including such things as our outlook, future capital expenditures, changes to the composition or level of our revenues, cash flow andliquidity, compound annual growth rates (CAGR), business strategies, competitive strengths, goals, the benefits of new initiatives,growth of our business and operations, plans and references to future successes, are forward-looking statements. Also, when weuse the words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “probably”, or similar expressions, we aremaking forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: risksand uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, thedevelopment and commercialization of the Company’s products, the Company’s distribution network, the cost and pricing of theCompany’s products, physician education, manufacturing, competition, dependence on collaborative partners and key suppliers,capital spending and funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure toforeign currency fluctuations and other risk factors discussed from time to time in the Company’s filings with the Securities andExchange Commission (the “SEC”). These and other factors are identified and described in more detail in the Company’s filings withthe SEC, including, without limitation, the Company’s recent Annual Report on Form 20-F and the Company’s other reports on Form6-K.

All forward-looking statements in this presentation are made as of the date of this presentation. We do not undertake, andexpressly disclaim, any intent or duty to update these forward-looking statements whether as a result of new information, futureevents or changes in expectations, other than as required by law.

This presentation is for information purposes only and does not constitute an offer of, or a solicitation to purchase or subscribe for,any securities. You should make your own independent examination of us and consult your own independent counsel, businessadvisors, tax advisors, investment advisors or other authorized advisors as to the legal, business, tax, investment or any othermatters pertaining to us or our securities.

2

Safe Harbor

A global, commercial stage medical technology company with 160 employees

Headquarters in Irvine, CA, manufacturing in Oxfordshire, UK

Focused on the $1.7B abdominal aortic aneurysm (“AAA”) repair market

Objective – To offer a patient focused, innovative portfolio approach to AAA treatment to treat the broadest range of patients

Aorfix™: The only globally approved AAA stent-graft for aortic neck angles up to 90 degrees

Altura®: New CE marked ultra low profile stent graft offering a simple, predictable and accurate solution for standard AAA anatomy

3

An Innovative Vascular Device Company

Broadest Anatomy Coverage

1 Medtech Ventures: Aortic Intervention Market (2014)

EVAR Market is Attractive with Strong Growth

EVAR market drivers ‒ Aging patient population‒ Increase in AAA screening ‒ Better outcome vs. surgery

$1.9 Billion by 20181

‒ 2016 WW market = $1.7B1

‒ 6% CAGR growth annually1

$1.4 $1.5 $1.6 $1.7 $1.8 $1.9

2013 2014 2015 2016 2017 2018

EVAR Market

$ Bi

llions

70%30%

High Neck AngulationLarge Neck DiametersShort Necks

Low Neck AngulationModerate Neck DiametersLonger Necks

Challenging AnatomyMainstream On-label

Lombard portfolio now allows patient-driven treatment choice

with “on-label” coverage of 85% of cases

Altura: Revolutionizing AAA treatment

Design Concept• Bilateral D-shaped (kissing stents) aortic grafts with overlapping iliac legs

Features/Benefits• Simple

− Ultra-low profile (14F) – percutaneous use− No cannulation − No polymer injection − Market leading inventory requirement

Altura – 6 product codes cover all patients Market leaders – 75+

• Predictable− Consistently shorter procedure time− Traditional wire & material stent graft

• Accurate − Proximal end can be recaptured and redeployed − Reverse Iliac deployment for exact placement − Offsetting bilateral stents allows use of total Aortic neck length

5

Altura provides a simple, predictable solution for standard AAA anatomy with the ability to deliver ‘out-patent’ and proctor free EVAR for many patients

Technology Comparisons

System Altura - Lombard Endurant II - Medtronic Ovation - TriVascular

French Size 14Fr (OD) 18-20Fr (OD) 14Fr (OD)

Complexity - Cannulation No cannulation required for contralateral deployment

Cannulation required forcontralateral deployment

Cannulation required forcontralateral deployment

Iliac Deployment Accurate reverse deployment Standard deployment Standard deployment

Recapture AbilityYes

Reposition during placement of proximal endograft

No No

Inventory 6 product codes 75 product codes 40+ product codes

Polymer No NoYes

Waiting time 20 mins before retraction.

Renal off-set positioning Yes No No

Stent Graft System

Altura: Device Overview – Comparative Analysis

Altura Launch Update

Controlled EU Launch in H1 2016• Sales team training completed in Q1• Live case at LINC congress in late January• Launched into selected reference centres in UK & Germany in late February

− Over 20 centers now active− Training centers set up in Riga Latvia with UK and Germany centers to follow in Q2− Significant physician interest in Altura as ‘out-patient’ EVAR stent graft

Broader International launch through H2 2016

US Approval Expectations and Milestones• Submit IDE - H2 2015• First patient enrollment – H1 2017• FDA approval anticipated in 2020

Japan approval 12 months after FDA

7

Aorfix halO™ Design Offers Unrivalled Flexibility

Competitors' “Z” type metallic ring designs are more rigid, may kink in tortuous anatomy increasing re-interventions

and poor clinical outcomes

8

Source: Images courtesy of Musgrove Park Hospital, Taunton

Aorfix: Unique Design to Address Tortuous Anatomy

Aorfix can provide better outcomes for patients with tortuous vascular anatomy

Proprietary halO Stent Technology™ featuring helical and circular design promotes flexibility

9

Before procedure 12 months after procedure

International Strategy

Four main EU markets: UK, Germany, Spain and Italy

• Established direct-markets: UK and Germany

• Country-specific distributors for other countries

Build out of EU sales team complete:• UK 5 sales territories • Germany 9 sales territories • Spain and Italy distributor network

Altura & IntelliFlex launches in 2016 expected to significantly boost EU sales through expanded sales teams

10

Italy supported by direct

sales head

Direct in UK & Germany withsales team of 14

Direct

Distributor

Spain

U.K.

Germany

ItalySpainSpain

1 Medtech Ventures: Aortic Intervention Market (2014)

Japanese Commercial Strategy

Japanese Market Dynamics• World’s second largest AAA market

• ~8,000 AAA procedures in 2014

• Well reimbursed ~$14,0001

Launch of Aorfix in Japan• Partnering with Medico’s Hirata

• Medico’s Hirata has significant experience in EVAR and a direct sales force trained in the Japanese AAA market due to a prior relationship with another AAA stent-graft company

• Unique regulatory approval for Aorfix to treat angulation ≤90 degrees granted in August 2014

• Formal launch in September 2014. Strong start with over 700 cases completed and 7.5% market share achieved in 18 months.

• Approval of latest IntelliFlex™ LP delivery system anticipated H2 2016

11

US Commercial Strategy

US is the largest AAA market valued at an estimated $800M in 2016

Aorfix FDA approved - full commercial launch November 2013

10 commercial sales territories + 2 Clinical staff• Recruited experienced EVAR reps or those with strong endovascular

experience• Equipped with most advanced field training tools

Aorfix cases completed in more than 180 US centers since launch using least invasive technique across all neck angles:

• ~50% below 60 degree neck angulation• More than half performed percutaneously

IntelliFlex™ LP Delivery system launch planned for Q4 2016/Q1 2017• Expect to drive increased share with existing users and open up new centers

12

IntelliFlex™ LP delivery system• Lower profile design – treat patients with

narrow access vessels• Exchange sheath – reduce vessel trauma• Increased control – accurate deployment • Intuitive & compact – ease of use

Thoracic (TEVAR) and Fenestrated (FEVAR) stent-grafts• Potential to develop both technology platforms to expand indications

within Endovascular Aneurysm Repair

13

New Product Development

0

2

4

6

8

10

12

14

16

18

20

2012 2013 2014 2015 2016

$MM

Lombard Revenue Contribution by Geography

14

2015 Performance: +14% (US +42%, JP +42%)

US Market

W Europe Direct Markets

2016 Projection (+20%)

Japan Market

ROW Distributor Markets

Financial Highlights

Income Statement – Q1 2016 revenue of $2.9 million was 15% below the prior year with the US down 24%

and Japan down 43% US sales headcount decreased by 60%, while sales productivity increased 109% Japan experienced sales declines as well, however, procedure volume increased 73%

y/y OPEX for the quarter was $8.3 million compared to $11.3 million in Q1 2015. Results

reflected a net loss of $7.6 million, or $0.38 loss per share, compared to a net loss of $9.5 million, or $0.59 loss per share, for the first quarter of 2015

Balance Sheet – Quarter-end cash (3/31) was $22.4 million compared to $32.3 million at the end of

2015 Cash burn was $3.5 million per month for the 2015 fiscal year, but reduced to $3.3

million in Q1 2016 Inventory was $8.0 million at 3/31, including ~ $1.0 million in Altura beginning to turn

in Q1 2016 Accounts receivable was $4.1 million at 3/31 w/ DSO at 55 days Debt at quarter-end was $23.3 million

FY 2016 Guidance• Remains unchanged with revenue growth of ~20.0% from 2015

15

Summary

A company with a clear strategy for global growth

• Patient focused portfolio approach launching in Europe in early 2016 will drive growth and market share capture from competitors:

− Altura - new AAA stent graft offering simple, accurate and predictable treatment option for patients with standard AAA anatomy and potential for ‘out-patient’ EVAR treatment

− Aorfix with IntelliFlex LP delivery system – only ‘on-label’ treatment for AAA patients with Aortic neck angulation above 60 degrees; most conformable stent graft to treat patients with tortuous iliac arteries

• IntelliFlex launch in US through established sales team will accelerate growth from existing and new users

• Experienced distribution partner in Japan with strong growth trajectory that will accelerate with forthcoming IntelliFlex LP launch

Two unique technology platforms for future innovation

16